TEPADINA®, an alkylating agent used with other medicines in the conditioning regimen before hematopoietic stem cell transplantation, is ADIENNE’s currently marketed product commercialized in 42 countries.

Since its approval in the EU in 2010, TEPADINA®, for which ODD has been granted in the European Union, U.S. and Switzerland, has attained a key role in many conditioning regimens before autologous and allogeneic HSCT for treating myeloma, lymphomas, acute leukemia and other malignant and non-malignant haematological diseases as well as for the treatment of solid tumours. In addition, it has already been approved in Switzerland, Israel, Russia and Hong Kong.

Conditioning is a fundamental preparatory step for engrafting hematopoietic stem cell transplants in the patient's marrow space and for controlling or eradicating the underlying disease. Bone marrow transplant, also called a stem cell transplant, is a procedure that infuses healthy cells, called stem cells, into a body to replace damaged or diseased bone marrow.

Bone marrow transplants may use cells from your own body (autologous trans-plant) or from a donor (allogeneic transplant). TEPADINA® can be used for both transplantations, autologous and allogeneic.